Minimal acute rejection in pediatric lung transplantation--does it matter?
Minimal acute rejection in pediatric lung transplantation--does it matter?
复制标题
小儿肺移植中的急性排斥反应最小——这重要吗？
DOI：
10.1111/j.1399-3046.2009.01268.x
复制
发表时间：
2010
影响因子：
1.3
通讯作者：
Solomon,Melinda
中科院分区：
文献类型：
--
作者：
Benden,Christian;Faro,Albert;Worley,Sarah;Arrigain,Susana;Aurora,Paul;Ballmann,Manfred;Boyer,Debra;Conrad,Carol;Eichler,Irmgard;Elidemir,Okan;Goldfarb,Samuel;Mallory,GeorgeB;Mogayzel,PeterJ;Parakininkas,Daiva;Solomon,Melinda
本登·C、法罗·A、沃利·S、阿里根·S、奥罗拉·P、鲍尔曼·M、博耶·D、康拉德·C、艾希勒一世、埃利德米尔·O、戈德法布·S、马洛里·GB、莫盖泽尔·PJ、帕拉金卡斯·D、所罗门·M、维斯纳·G、甜蜜的SC、丹齐格-伊萨科夫洛杉矶。儿科肺移植中最小的急性排斥反应--重要吗？
儿科移植2010年：14：534-539。摘要：在成人肺移植中，单个微小的AR发作是独立于其他因素的BOS的显著预测因素。然而，儿童单次最小AR发作的意义尚不清楚。进行了一项多中心的回顾性分析，以确定孤立的单次AR发作是否与儿童BOS风险增加有关。评估了BOS、死亡或再移植的危险因素，以及BOS、死亡或再移植的综合结果。原始数据包括577名患者(21岁， )。共有383名受试者符合这项研究的条件。15%的患者发展为BOS，13%的患者在移植后一年内死亡或再次接受移植。在多因素生存模型中，在单次最小AR(A1)发作(HR 1.7，95%CI 0.6 4~4.8；p = 0.2 8)后，未发现发生BOS的显著风险。即使在第二个最小的AR发作之后，BOS也没有显著的风险。然而，轻度AR(A2)的一次发作与移植后一年内BOS的风险增加了一倍。在这个选定的队列中，单个微小的AR发作与肺移植后一年内BOS风险的增加无关，这与先前在成人中的报道相反。
Benden C, Faro A, Worley S, Arrigain S, Aurora P, Ballmann M, Boyer D, Conrad C, Eichler I, Elidemir O, Goldfarb S, Mallory GB, Mogayzel PJ, Parakininkas D, Solomon M, Visner G, Sweet SC, Danziger‐Isakov LA. Minimal acute rejection in pediatric lung transplantation – Does it matter?.
Pediatr Transplantation 2010: 14:534–539. © 2010 John Wiley & Sons A/S.Abstract:In adult lung transplantation, a single minimal AR episode is a significant predictor of BOS independent of other factors. However, the significance of single minimal AR episodes in children is unknown. A retrospective, multi‐center analysis was performed to determine whether isolated single AR episodes are associated with an increased BOS risk in children. Risk factors for BOS, death, or re‐transplantation, and a combined outcome of BOS, death, or re‐transplantation were assessed. Original data included 577 patients (<21 yr of age). A total of 383 subjects were eligible for the study. Fifteen percent of patients developed BOS, and 13% of patients either died or underwent re‐transplant within one‐yr post‐transplant. In the multivariable survival model for time to BOS, there was no significant risk to developing BOS after a single minimal AR (A1) episode (HR 1.7, 95% CI 0.64–4.8; p = 0.28). Even after a second minimal AR episode, no significant risk for BOS was appreciated. However, a single episode of mild AR (A2) was associated with twice the risk of BOS within one‐yr post‐transplant. In this select cohort, a single minimal AR episode was not associated with an increased risk for BOS within one yr following lung transplantation, in contrast to previous reports in adults.